IL17A and rheumatoid arthritis: However, despite a strong biological background, the efficacy of secukinumab (a fully human monoclonal antibody binding and neutralizing selectively IL-17A) in RA was modest when compared with abatacept (86), with limited efficacy in patients who were poor responders to TNF inhibitors (87).